Medgenics (MDGN) Misses Q2 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Medgenics Reports Second Quarter 2016 Financial Results
August 4, 2016 8:03 AM EDTPHILADELPHIA, PA -- (Marketwired) -- 08/04/16 -- Medgenics, Inc. (NYSE MKT: MDGN)
Initiated Phase 2/3 study of lead program in mGluR+ ADHD Entered into collaboration for second pediatric product in Inflammatory Bowel Disease Strengthened balance sheet with successful financingMedgenics, Inc. (NYSE MKT: MDGN) (the Company) today announced second quarter 2016 financial results and provided a business update.
"We are very pleased with the... More
